{"generic":"Metreleptin","drugs":["Metreleptin","Myalept"],"mono":{"0":{"id":"jyaks0","title":"Generic Names","mono":"Metreleptin"},"1":{"id":"jyaks1","title":"Dosing and Indications","sub":[{"id":"jyaks1b4","title":"Adult Dosing","mono":"<ul><li><b>Lipodystrophy, Congenital or acquired generalized:<\/b> (men and women 40 kg or less) initial dose, 0.06 mg\/kg SUBQ once daily; adjust dose in increments of 0.02 mg\/kg based on clinical response and tolerability; MAX dose, 0.13 mg\/kg\/day<\/li><li><b>Lipodystrophy, Congenital or acquired generalized:<\/b> (men greater than 40 kg) initial dose, 2.5 mg SUBQ once daily; adjust dose in increments of 1.25 to 2.5 mg based on clinical response and tolerability; MAX dose, 10 mg\/day<\/li><li><b>Lipodystrophy, Congenital or acquired generalized:<\/b> (women greater than 40 kg) initial dose, 5 mg SUBQ once daily; adjust dose in increments of 1.25 to 2.5 mg based on clinical response and tolerability; MAX dose, 10 mg\/day<\/li><\/ul>"},{"id":"jyaks1b5","title":"Pediatric Dosing","mono":"<ul><li><b>Lipodystrophy, Congenital or acquired generalized:<\/b> (males and females 40 kg or less) initial dose, 0.06 mg\/kg SUBQ once daily; adjust dose in increments of 0.02 mg\/kg based on clinical response and tolerability; MAX dose, 0.13 mg\/kg\/day<\/li><li><b>Lipodystrophy, Congenital or acquired generalized:<\/b> (males greater than 40 kg) initial dose, 2.5 mg SUBQ once daily; adjust dose in increments of 1.25 to 2.5 mg based on clinical response and tolerability; MAX dose, 10 mg\/day<\/li><li><b>Lipodystrophy, Congenital or acquired generalized:<\/b> (females greater than 40 kg) initial dose, 5 mg SUBQ once daily; adjust dose in increments of 1.25 to 2.5 mg based on clinical response and tolerability; MAX dose, 10 mg\/day<\/li><\/ul>"},{"id":"jyaks1b6","title":"Dose Adjustments","mono":"<ul><li><b>geriatrics:<\/b> start at the low end of the dosing range<\/li><li><b>concomitant use of insulin or insulin secretagogues:<\/b> dose adjustments of insulin or insulin secretagogues may be required; reductions could be large<\/li><li><b>patients at risk for pancreatitis:<\/b> discontinue by tapering the dose over 1 week<\/li><\/ul>"},{"id":"jyaks1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Lipodystrophy, Congenital or acquired generalized<br\/>"}]},"2":{"id":"jyaks2","title":"Black Box Warning","mono":"<b>Subcutaneous (Powder for Solution)<\/b><br\/>Anti-metreleptin antibodies with neutralizing activity have been identified in patients treated with metreleptin. The consequences are not well characterized but could include inhibition of endogenous leptin action and\/or loss of metreleptin efficacy. Severe infection and\/or worsening metabolic control have been reported. Test for anti-metreleptin antibodies with neutralizing activity in patients who develop severe infections or show signs suspicious for loss of metreleptin efficacy during treatment. T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy, both treated and not treated with metreleptin. Carefully consider the benefits and risks of treatment with metreleptin in patients with significant hematologic abnormalities and\/or acquired generalized lipodystrophy. Metreleptin is available only through a restricted program called the Myalept(TM) REMS Program.<br\/>"},"3":{"id":"jyaks3","title":"Contraindications\/Warnings","sub":[{"id":"jyaks3b9","title":"Contraindications","mono":"<ul><li>hypersensitivity, severe, to metreleptin or any product component<\/li><li>obesity, general, not associated with congenital leptin deficiency; not effective in treating general obesity and development of anti-metreleptin antibodies with neutralizing activity has been reported<\/li><\/ul>"},{"id":"jyaks3b10","title":"Precautions","mono":"<ul><li>anti-metreleptin antibodies with neutralizing activity to leptin associated with adverse events consistent with loss of endogenous leptin activity and\/or loss of efficacy have been reported; monitoring recommended if severe infections develop or loss of efficacy is suspected<\/li><li>T-cell lymphoma has been reported during therapy in patients with acquired generalized lipodystrophy; consider risks versus benefits of treatment in patients with significant hematologic abnormalities (leukopenia, neutropenia, bone marrow abnormalities, lymphoma, lymphadenopathy) or acquired lipodystrophies<\/li><li>autoimmune disease; progression of autoimmune hepatitis and membranoproliferative glomerulonephritis, associated with massive proteinuria and renal failure, have been reported<\/li><li>infants and neonates; serious adverse events (eg, &quot;gasping syndrome&quot;) and death have been reported with benzyl alcohol, which is contained in the product when reconstituted with Bacteriostatic Water for Injection; preservative-free sterile Water for Injection recommended for reconstitution<\/li><li>Risk Evaluation and Mitigation Strategy (REMS) program; product is only available through this program due to anti-metreleptin antibody development risk and lymphoma risk; more information at www.myaleptrems.com or 1-855-6MYALEPT<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"jyaks3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"jyaks3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jyaks4","title":"Drug Interactions","sub":{"1":{"id":"jyaks4b14","title":"Major","mono":"<ul><li>Acetohexamide (established)<\/li><li>Chlorpropamide (established)<\/li><li>Gliclazide (established)<\/li><li>Glimepiride (established)<\/li><li>Glipizide (established)<\/li><li>Gliquidone (established)<\/li><li>Glyburide (established)<\/li><li>Insulin (established)<\/li><li>Insulin Aspart, Recombinant (established)<\/li><li>Insulin Bovine (established)<\/li><li>Insulin Degludec (established)<\/li><li>Insulin Detemir (established)<\/li><li>Insulin Glulisine (established)<\/li><li>Insulin Lispro, Recombinant (established)<\/li><li>Nateglinide (established)<\/li><li>Repaglinide (established)<\/li><\/ul>"}}},"5":{"id":"jyaks5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Endocrine metabolic:<\/b>Hypoglycemia (13%), Weight decreased (13%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (10%)<\/li><li><b>Neurologic:<\/b>Headache (13%)<\/li><\/ul><b>Serious<\/b><br\/><b>Immunologic:<\/b>Antibody development, Large cell anaplastic lymphoma, T-cell lymphoma<br\/>"},"6":{"id":"jyaks6","title":"Drug Name Info","sub":{"0":{"id":"jyaks6b17","title":"US Trade Names","mono":"Myalept<br\/>"},"3":{"id":"jyaks6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jyaks6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jyaks7","title":"Mechanism Of Action","mono":"metreleptin binds to and activates the human leptin receptor, mimicking native leptin, which is responsible for signaling the CNS with the status of energy stores in the body.<br\/>"},"8":{"id":"jyaks8","title":"Pharmacokinetics","sub":[{"id":"jyaks8b23","title":"Absorption","mono":"Tmax, subQ: 4 hours <br\/>"},{"id":"jyaks8b24","title":"Distribution","mono":"Vd: 370 to 463 mL\/kg <br\/>"},{"id":"jyaks8b25","title":"Metabolism","mono":"Renal: major route; no evidence of systemic metabolism <br\/>"},{"id":"jyaks8b26","title":"Excretion","mono":"Total body clearance: delayed in the presence of leptin antibodies <br\/>"},{"id":"jyaks8b27","title":"Elimination Half Life","mono":"3.8 to 4.7 hours <br\/>"}]},"9":{"id":"jyaks9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>reconstitute with 2.2 mL of bacteriostatic water for injection or sterile water for injection and gently swirl; do not shake or vigorously agitate<\/li><li>reconstituted solution with bacteriostatic water for injection can be used for 3 days when stored under refrigeration (36 to 46 degrees F or 2 to 8 degrees C) and protected from light<\/li><li>use preservative-free sterile water for injection to reconstitute metreleptin for use in neonates and infants; administer reconstituted solution immediately and discard unused portion<\/li><li>administer subQ in the abdomen, thigh, or upper arm; rotate injection sites; avoid IM injection<\/li><li>may administer doses greater than 1 mL as 2 injections to avoid injection site discomfort<\/li><\/ul>"},"10":{"id":"jyaks10","title":"Monitoring","mono":"<ul><li>improvement in symptoms from leptin deficiency complications may indicate efficacy<\/li><li>neutralizing antibody testing in patients with loss of efficacy or severe infections during therapy<\/li><li>serum glucose, in patients on concurrent insulin or insulin secretagogue therapy<\/li><li>triglyceride levels; during treatment discontinuation in patients at risk for pancreatitis<\/li><li>total benzyl alcohol metabolic load in pediatric patients, especially premature or low-birthweight infants and with large doses<\/li><\/ul>"},"11":{"id":"jyaks11","title":"How Supplied","mono":"<b>Myalept<\/b><br\/>Subcutaneous Powder for Solution: 11.3 MG<br\/>"},"13":{"id":"jyaks13","title":"Clinical Teaching","mono":"<ul><li>Counsel patient to report severe infections or new loss of metabolic control (eg, diabetes) during treatment.<\/li><li>Instruct patient to report symptoms of lymphoma.<\/li><li>Tell patient to immediately report symptoms of hypersensitivity.<\/li><li>Side effects may include headache, hypoglycemia, weight loss, or abdominal pain.<\/li><li>Instruct patient treated concurrently with insulin or insulin secretagogues to closely monitor blood glucose.<\/li><li>Counsel patient with autoimmune disease to report symptom worsening.<\/li><li>Tell patient that drug should only be self-administered by subQ injection. Instruct patient on proper injection technique.<\/li><li>Instruct caregivers administering medication to newborns and infants to reconstitute medication only with preservative-free water for injection.<\/li><li>Advise patient to discard any remaining solution reconstituted with water for injection after administration.<\/li><li>Counsel patient against sudden discontinuation of this drug.<\/li><\/ul>"}}}